Abstract Background Intravenous immunoglobulin (IVIg) is currently in clinical study for
Alzheimer's disease (AD). However, preclinical investigations are required to better …

Background Human intravenous immunoglobulin (hIVIG) preparation is indicated for treating
primary immunodeficiency disorders associated with impaired humoral immunity. hIVIG is …

Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical
studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals …

Background Purified intravenous immunoglobulin (IVIG) obtained from the plasma of healthy
humans is indicated for the treatment of primary immunodeficiency disorders associated with …

Vascular cognitive impairment and dementia (VCID) is the second most common form of
dementia behind Alzheimer's disease (AD). It is estimated that 40% of AD patients also have …

Background Intravenous Immunoglobulin (IVIG) is under study as an agent for
immunotherapy of Alzheimer's disease (AD). Positive results of a phase 2 double-blind …

Objective: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment
for mild to moderate Alzheimer disease (AD) dementia. Methods: In a phase 3, double-blind …

Alzheimer's disease (AD) is mainly characterized by amyloid beta (Aβ) plaque deposition
and neurofibrillary tangle formation due to tau hyperphosphorylation. It has been shown that …

Current treatment options for Alzheimer's disease (AD) exert only a shortlived effect on
disease symptoms. Active and passive immunotherapy have both been shown to be …

Gammagard IVIg is a therapeutic approach to treat Alzheimer's disease currently in phase 3
clinical trials. Despite the reported efficacy of the approach the mechanism of action is poorly …